Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Buck Website

Christopher B. Buck, Ph.D.

Selected Publications

1)  Tsang SH, Wang X, Li J, Buck CB, You J.
Host DNA damage response factors localize to merkel cell polyomavirus DNA replication sites to support efficient viral DNA replication.
J. Virol. 88: 3285-97, 2014.
2)  Pastrana DV, Fitzgerald PC, Phan GQ, Raiji MT, Murphy PM, McDermott DH, Velez D, Bliskovsky V, McBride AA, Buck CB.
A divergent variant of the eleventh human polyomavirus species, saint louis polyomavirus.
Genome Announc. 1, 2013.
3)  Pastrana DV, Ray U, Magaldi TG, Schowalter RM, Cuburu N, Buck CB.
BK Polyomavirus Genotypes Represent Distinct Serotypes with Distinct Entry Tropism.
J. Virol. 87: 10105-13, 2013.
4)  Handisurya A, Day PM, Thompson CD, Buck CB, Pang YS, Lowy DR, Schiller JT.
Characterization of Mus musculus Papillomavirus 1 (MusPV1) Infection In Situ Reveals an Unusual Pattern of Late Gene Expression and Capsid Protein Localization.
J. Virol. 87: 13214-25, 2013.
5)  Li J, Wang X, Diaz J, Tsang SH, Buck CB, You J.
Merkel Cell Polyomavirus Large T Antigen Disrupts Host Genomic Integrity and Inhibits Cellular Proliferation.
J. Virol. 87: 9173-88, 2013.
6)  Schowalter RM, Buck CB.
The merkel cell polyomavirus minor capsid protein.
PLoS Pathog. 9: e1003558, 2013.
7)  Buck CB, Day PM, Trus BL.
The papillomavirus major capsid protein L1.
Virology. 445: 169-74, 2013.
8)  Wang X, Li J, Schowalter RM, Jiao J, Buck CB, You J.
Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication.
PLoS Pathog. 8: e1003021, 2012.
9)  Bouvard V, Baan R, Grosse Y, Lauby-Secretan B, El Ghissassi G, Benbrahim-Tallaa L, Guha N, Straif K.
Carcinogenicity of malaria and of some polyomaviruses.
Lancet Oncol. 13: 339-40, 2012.
10)  Buck CB, Phan GQ, Raiji MT, Murphy PM, McDermott DH, McBride AA.
Complete genome sequence of a tenth human polyomavirus.
J. Virol. 86: 10887, 2012.
11)  Schowalter RM, Reinhold WC, Buck CB.
Entry Tropism of BK and Merkel Cell Polyomaviruses in Cell Culture.
PLoS ONE. 7: e42181, 2012.
12)  Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
J. Clin. Invest. 122: 4606-20, 2012.
13)  Lieleg O, Lieleg C, Bloom J, Buck CB, Ribbeck K.
Mucin biopolymers as broad-spectrum antiviral agents.
Biomacromolecules. 13: 1724-32, 2012.
14)  Handisurya A, Day PM, Thompson CD, Buck CB, Kwak K, Roden RB, Lowy DR, Schiller JT.
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.
Virology. 433: 385-94, 2012.
15)  Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, Buck CB.
Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients.
PLoS Pathog. 8: e1002650, 2012.
16)  Schrama D, Buck CB, Houben R, Becker JC.
No evidence for association of HPyV6 or HPyV7 with different skin cancers.
J. Invest. Dermatol. 132: 239-41, 2012.
17)  Pastrana DV, Wieland U, Silling S, Buck CB, Pfister H.
Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer.
Med Microbiol Immunol. 201: 17-23, 2012.
18)  Neu U, Hengel H, Blaum BS, Schowalter RM, Macejak D, Gilbert M, Wakarchuk WW, Imamura A, Ando H, Kiso M, Arnberg N, Garcea RL, Peters T, Buck CB, Stehle T.
Structures of Merkel Cell Polyomavirus VP1 Complexes Define a Sialic Acid Binding Site Required for Infection.
PLoS Pathog. 8: e1002738, 2012.
19)  Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G.
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.
J. Immunol. 188: 714-23, 2012.
20)  Buck CB, Trus BL.
The papillomavirus virion: a machine built to hide molecular Achilles' heels.
Adv. Exp. Med. Biol. 726: 403-22, 2012.
21)  Faust H, Pastrana DV, Buck CB, Dillner J, Ekström J.
Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin.
J. Infect. Dis. 203: 1096-100, 2011.
22)  Schiller JT, Buck CB.
Cutaneous squamous cell carcinoma: a smoking gun but still no suspects.
J. Invest. Dermatol. 131: 1595-6, 2011.
23)  Schowalter RM, Pastrana DV, Buck CB.
Glycosaminoglycans and sialylated glycans sequentially facilitate merkel cell polyomavirus infectious entry.
PLoS Pathog. 7: e1002161, 2011.
24)  Buck CB, Lowy DR.
Immune readouts may have prognostic value for the course of merkel cell carcinoma, a virally associated disease.
J. Clin. Oncol. 29: 1506-8, 2011.
25)  Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramqvist T, Norkin LC.
Taxonomical developments in the family Polyomaviridae.
Arch Virol. 156: 1627-34, 2011.
26)  Pastrana DV, Pumphrey KA, Cuburu N, Schowalter RM, Buck CB.
Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.
Virology. 405: 20-5, 2010.
27)  Huang H, Buck CB, Lambert PF.
Inhibition of gamma secretase blocks HPV infection.
Virology. 407: 391-6, 2010.
28)  Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB.
Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin.
Cell Host Microbe. 7: 509-15, 2010.
29)  Graham BS, Kines RC, Corbett KS, Nicewonger J, Johnson TR, Chen M, LaVigne D, Roberts JN, Cuburu N, Schiller JT, Buck CB.
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.
Mucosal Immunol. 3: 475-86, 2010.
30)  Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB.
Papillomavirus infection requires {gamma} secretase.
J Virol. 84: 10661-70, 2010.
31)  Senger T, Schädlich L, Textor S, Klein C, Michael KM, Buck CB, Gissmann L.
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.
Vaccine. 28: 1583-93, 2010.
32)  Pérez-Andino J, Buck CB, Ribbeck K.
Adsorption of human papillomavirus 16 to live human sperm.
PLoS ONE. 4: e5847, 2009.
33)  Giraud G, Ramqvist T, Pastrana DV, Pavot V, Lindau C, Kogner P, Orrego A, Buck CB, Allander T, Holm S, Gustavsson B, Dalianis T.
DNA from KI, WU and Merkel cell polyomaviruses is not detected in childhood central nervous system tumours or neuroblastomas.
PLoS ONE. 4: e8239, 2009.
34)  Buck CB, Lowy DR.
Getting stronger: the relationship between a newly identified virus and Merkel cell carcinoma.
J. Invest. Dermatol. 129: 9-11, 2009.
35)  Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, Chang Y, Buck CB, Moore PS.
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays.
Int. J. Cancer. 125: 1250-6, 2009.
36)  Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB.
Quantitation of human seroresponsiveness to Merkel cell polyomavirus.
PLoS Pathog. 5: e1000578, 2009.
37)  Talwar GP, Dar SA, Rai MK, Reddy KV, Mitra D, Kulkarni SV, Doncel GF, Buck CB, Schiller JT, Muralidhar S, Bala M, Agrawal SS, Bansal K, Verma JK.
A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens.
Int. J. Antimicrob. Agents. 32: 180-5, 2008.
38)  Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL.
Arrangement of L2 within the papillomavirus capsid.
J. Virol. 82: 5190-7, 2008.
39)  Buck CB.
Defensins' offensive play: exploiting a viral achilles' heel.
Cell Host Microbe. 3: 3-4, 2008.
Full Text Article. [Journal]
40)  Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB.
A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
J. Virol. 81: 13927-31, 2007.
41)  Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT.
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
Nat. Med. 13: 857-61, 2007.
42)  Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
J. Virol. 81: 8784-92, 2007.
43)  Buck CB, Thompson CD.
Production of papillomavirus-based gene transfer vectors.
Curr Protoc Cell Biol. 26: 26.1, 2007.
44)  Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT.
Carrageenan is a potent inhibitor of papillomavirus infection.
PLoS Pathog. 2: e69, 2006.
45)  Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT.
Human alpha-defensins block papillomavirus infection.
Proc. Natl. Acad. Sci. U.S.A. 103: 1516-21, 2006.
46)  Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB.
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 337: 365-72, 2005.
47)  Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT.
Maturation of papillomavirus capsids.
J. Virol. 79: 2839-46, 2005.
48)  Buck CB, Pastrana DV, Lowy DR, Schiller JT.
Efficient intracellular assembly of papillomaviral vectors.
J. Virol. 78: 751-7, 2004.
49)  Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT.
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology. 321: 205-16, 2004.
50)  Shen X, Wong SB, Buck CB, Zhang J, Siliciano RF.
Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes.
J. Immunol. 169: 4222-9, 2002.
51)  Buck CB, Shen X, Egan MA, Pierson TC, Walker CM, Siliciano RF.
The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.
J. Virol. 75: 181-91, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/23/2014.